Monday, September 26, 2016 9:36:00 AM
"Changes at the Top for Endo Could Benefit Its Smaller Partners The promotion of Paul Campanelli to CEO indicates a change in the company's focus from acquiring other firms to its roots as a generic pharmaceutical firm.
[...]
Another beneficiary of this recent move by Endo may be its much smaller partner, Intellipharmaceutics International (IPCI), which has a long-standing partnership agreement for the marketing of generic Focalin XR (Dexmethylphenidate hydrochloride extended release), a $760 million in annual sales drug for ADHD. PCI originally signed its deal with Par in 2005 for all dosage strengths of Focalin XR, and while two dosage strengths (15 mg and 30 mg) of the generic were approved by the FDA and launched by Par in November 2013, four more (5, 10, 20 and 40 mg) need additional approval by the agency to meet new regulatory requirements. While IPCI has stated that it is working with Par (now Endo) to obtain the additional approvals, and it is confident Endo will launch as soon as possible, the new emphasis by Endo on operations removes some of the risk of this partnership that may have been perceived after Par was folded into Endo. What's more, IPCI now may find a more focused potential partner in Endo for other products in its pipeline which have yet be partnered. These include two branded (NDA track) drug candidates, seven additional generic drug ANDA applications, and up to 20 opiate drug candidates with potential for the easier 505(b)(2) regulatory approval route with the FDA. While ENDP shares responded favorably today to its news release, IPCI shares surged mysteriously yesterday -- so mysteriously IPCI felt it necessary to issue a press release disavowing knowledge of "any corporate developments that may have caused the recent movement in the company's share price". Perhaps, however, the corporate development providing a boost to IPCI came from partner Endo, instead."
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - IPCI • PR Newswire (Canada) • 06/08/2023 05:30:00 PM
- Canadian Investment Regulatory Organization Trade Resumption - IPCI • PR Newswire (Canada) • 06/08/2023 05:28:00 PM
- Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results • PR Newswire (Canada) • 06/06/2023 10:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM